CMO Pharma-Bio Industry Capital Project Activity Continues to Soar

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Contract Manufacturing Organizations (CMOs) already were an important factor in the drug industry's toolbox pre-COVID, but the enormous demand generated by the pandemic catapulted their value even higher. They responded by boosting capacity and going to 24/7 shifts where possible.

Drug companies can bring a product to market in two ways: by manufacturing the product in their own facilities; or by procuring and buying capacity from a contract CMO. CMOs offer comprehensive services that extend from drug development all the way through to manufacturing and packaging. The top CMOs include Lonza, Catalent and ThermoFisher (Patheon.) There also are a number of major drug companies that offer CMO functions, including AbbVie, Boehringer Ingelheim, Gilead, Merck and Pfizer.

Almost two years in to the pandemic, CMOs are still investing in expansions and upgrades. Industrial Info is tracking 275 active CMO projects in North America, worth a potential investment of more than $7 billion. Of those projects, 167 have a future kickoff date, and represent almost $5 billion in spending. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of detailed reports.

Click on the image at right for a map showing CMO capital project activity in North America.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.